Critical reviews in oncology/hematology最新文献

{"title":"FGFR-Altered Urothelial Carcinoma in the EV-Pembrolizumab Era: Rationale and Emerging Data for Upfront Triplet Strategies.","authors":"Claudia Maria Ascione, Raffaella Congi, Stella Feliciello, Carmine Caso, Felice Crocetto, Ciro Imbimbo, Alberto Servetto, Fabrizio Di Costanzo, Roberto Bianco, Daniela Esposito, Luigi Formisano","doi":"10.1016/j.critrevonc.2026.105641","DOIUrl":"https://doi.org/10.1016/j.critrevonc.2026.105641","url":null,"abstract":"<p><p>Urothelial cancer (UC) is a common malignancy with a significant incidence worldwide, particularly in Europe and North America. Approximately 5% of patients have de novo metastatic disease at the time of initial diagnosis. The combination of Enfortumab vedotin and Pembrolizumab recently transformed the first-line treatment landscape, providing better clinical outcomes and greater tolerability compared to traditional cisplatin-based therapies. However, alterations in fibroblast growth factor receptor (FGFR) signaling may diminish the effectiveness of Immune Checkpoint Inhibitors (ICIs), underscoring the need for novel combination therapies. This review examines emerging evidence supporting combination strategies incorporating pan-FGFR tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma, focusing on their potential integration with first-line doublet regimens. Ongoing and future clinical studies will be essential to define the clinical value of these combinations and to advance precision immunotherapy strategies guided by genomic alterations, to improve outcomes for patients with UC.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"105641"},"PeriodicalIF":5.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149129598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Generic Tumor: Engineering Patient-Specific Immune Ecosystems for Cancer.","authors":"Samira Anvari, Jalal Naghinezhad, Reza Farokhi, Mahshid Akhavan Rahnama, Saghar Hoseinzadeh, Mohsen Nikbakht, Mohammad Ahmadvand","doi":"10.1016/j.critrevonc.2026.105611","DOIUrl":"https://doi.org/10.1016/j.critrevonc.2026.105611","url":null,"abstract":"<p><p>Cancer immunotherapy has transformed the treatment landscape of malignancies; however, durable clinical responses remain limited by interpatient heterogeneity, tumor evolution, antigen loss, and variability in immune recognition. Advances in genomic sequencing, neoantigen discovery, immunopeptidomics, mRNA-based therapeutics, and cellular engineering have expanded opportunities for developing individualized immunotherapeutic strategies based on patient-specific tumor and immune characteristics. This review examines the state of personalized cancer immunotherapy, with emphasis on individualized neoantigen-specific therapies (iNeST), neoantigen vaccines, mRNA-based antigen delivery platforms, engineered T-cell approaches, and computational methods for antigen prioritization and immune-response prediction. We summarize the biological rationale, preclinical and clinical evidence, and limitations of these approaches, while considering their translational potential and clinical feasibility. We examine the relationships among tumor mutational landscapes, neoantigen immunogenicity, antigen processing and presentation, HLA restriction, immune-cell engineering, and computational immunology. We further assess key barriers to clinical implementation, including limitations in neoantigen prediction and validation, intratumoral heterogeneity, antigen evolution and loss, manufacturing complexity, scalability, regulatory requirements, and the need for prospective clinical validation. Overall, current evidence supports personalized immunotherapy as a promising approach for improving the precision of cancer treatment, but its clinical application remains constrained by biological, technical, manufacturing, regulatory, and clinical challenges. Future progress will require more accurate and experimentally validated neoantigen identification, improved computational and immunologic modeling, robust manufacturing and quality-control processes, and prospective clinical studies demonstrating safety, feasibility, and therapeutic benefit. This review evaluates the current evidence, identifies knowledge gaps, and outlines priorities for the responsible clinical development of individualized cancer immunotherapy.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"105611"},"PeriodicalIF":5.6,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149013308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Paraneoplastic glomerulopathy associated with solid tumors: A review, [Crit. Rev. Oncol./Hematol. 227 (2026) 105550].","authors":"Mengsi Hu, Qiqi Ma, Liguang Wang, Zhimei Lv, Rong Wang","doi":"10.1016/j.critrevonc.2026.105576","DOIUrl":"https://doi.org/10.1016/j.critrevonc.2026.105576","url":null,"abstract":"","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"105576"},"PeriodicalIF":5.6,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker-driven insights into immune checkpoint inhibitor therapy in small-cell lung cancer.","authors":"Shuxing Wang, Xinrui Zhao, Yue Zeng, Wenxin Li, Jumin Huang, Elaine Lai-Han Leung, Shaun Png, Aoxi Liang, Yiyang Li, Qian Guan, Dan Fan, Jialu Liu, Lu Chen, Shijiao Yao, Min Lu, Edward E Graves, Julien Sage, Fang Wu","doi":"10.1016/j.critrevonc.2026.105517","DOIUrl":"10.1016/j.critrevonc.2026.105517","url":null,"abstract":"<p><p>Small cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options, and the integration of immune checkpoint inhibitors (ICIs) into treatment regimens has reshaped the therapeutic landscape. However, challenges such as rapid resistance and lack of effective predictive biomarkers remain. This review highlights the pivotal roles of biomarkers in SCLC, underscoring their contributions to treatment resistance across tumor-intrinsic mechanisms, immune landscape of the tumor microenvironment (TME) and systemic host factors. Tumor-intrinsic features, including molecular subtypes, genetic alterations such as TP53 and RB1 mutations, and tumor mutation burden (TMB), have shown varying associations with ICI efficacy. Notably, the SCLC-I (inflamed) molecular subtype appears more responsive to immunotherapy. Within the TME, programmed cell death ligand 1 expression, tumor-infiltrating lymphocytes (TILs), regulatory T cells, myeloid-derived suppressor cells, and tissue-associated cytokines and chemokines contribute to immune modulation. High CD8⁺ TILs are linked to better outcomes, while increased immunosuppressive populations often suppress anti-tumor response. Systemic factors, encompassing tumor-derived (ctDNA, CTCs, tumor-derived EVs) and host-derived (circulating immune cell phenotypes, MHC expression, immune profile, baseline clinical characteristics) components, and psychological factors, provide valuable insights into treatment response and prognosis. Further research is needed to validate biomarkers and investigate combination approaches to overcome resistance, offering hope for improved patient outcomes in SCLC.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"105517"},"PeriodicalIF":5.6,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mesenchymal stem cell infusion to accelerate hematopoietic recovery after transplantation: A comprehensive systematic review of clinical studies (2000-2025).","authors":"Noushin Pouryazdanpanah, Vahid Moazed, Roohollah Mirzaee Khalilabadi, Tania Dehesh, Alireza Farsinejad","doi":"10.1016/j.critrevonc.2025.104875","DOIUrl":"10.1016/j.critrevonc.2025.104875","url":null,"abstract":"<p><strong>Background: </strong>Hematopoietic stem cell transplantation (HSCT) is a standard therapy for various hematologic diseases, yet delayed engraftment remains a significant challenge. Mesenchymal stem cells (MSCs) have attracted attention for their potential to enhance hematopoietic recovery due to their immunomodulatory and supportive functions. This systematic review aimed to evaluate the clinical impact of MSC infusion on engraftment outcomes after HSCT.</p><p><strong>Method: </strong>We systematically searched PubMed, Embase, Scopus, Web of Science, and Cochrane Library for clinical studies published between 2000 and 2025. Eligible studies included randomized trials, cohort studies, and case series that assessed MSCs for improving engraftment. Data were synthesized qualitatively.</p><p><strong>Result: </strong>Forty-seven studies involving 1777 patients were included. MSCs were primarily derived from bone marrow or umbilical cord and administered intravenously. Approximately 79 % of the studies reported enhanced engraftment, with particular benefit for platelet recovery. The average neutrophil and platelet engraftment times in MSC recipients were 13.96 and 21.61 days, respectively. No serious adverse events related to MSC infusion were reported.</p><p><strong>Conclusion: </strong>Current clinical evidence supports the safety and potential efficacy of MSCs in promoting hematopoietic engraftment, especially platelet recovery, in HSCT recipients. Further high-quality randomized trials are required to confirm these findings. This systematic review is registered in PROSPERO (CRD420251082387).</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104875"},"PeriodicalIF":5.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups.","authors":"Mohammed S Beshr, Rana H Shembesh, Abdelaziz H Salama, Imane Chenfouh, Sarah M Alfaqaih, Abdallah Khashan, Arwi Omar Kara, Maram Abuajamieh, Eman Basheer, Zahraa Alla Ansaf, Esraa Arhaym, Mohamedhen Vall Nounou, Mohamed E Ali, Elizabeth C Smyth, Muhammed Elhadi, Markus Moehler","doi":"10.1016/j.critrevonc.2025.104876","DOIUrl":"10.1016/j.critrevonc.2025.104876","url":null,"abstract":"<p><strong>Background: </strong>Advanced esophageal cell carcinoma (ESCC) is associated with poor survival outcomes. PD-1/PD-L1 inhibitors have been approved for the treatment of advanced ESCC. We aim to study PD-1/PD-L1 inhibitors across other variables in advanced ESCC, including data presented at the September 2024 FDA Oncologic Drugs Advisory Committee (ODAC) meeting.</p><p><strong>Methods: </strong>On February 28, 2025, we conducted a comprehensive search using PubMed, Web of Science, Scopus, and the Cochrane Library to identify randomized clinical trials evaluating PD-1/PD-L1 inhibitors in advanced ESCC. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Subgroup analyses were performed based on the following variables: age, gender, smoking status, ECOG performance status, liver metastasis, disease stage (locally advanced vs. metastatic), combined positive score (CPS; particularly with cutoff values of CPS 5 and CPS 1-9), and tumor area positivity (TAP). Effect sizes were estimated using the hazard ratio (HR) with random effects model.</p><p><strong>Results: </strong>Out of 5514 articles screened, only 13 papers were included, involving 6672 patients. PD-1/PD-L1 inhibitors significantly improved OS in both first- and second-line. In the first-line setting (combined with chemotherapy), they reduced the risk of death by 32 % (HR: 0.68; 95 % CI: 0.63-0.74, p < 0.001), while in the second-line setting (used as monotherapy), they reduced mortality by 27 % (HR: 0.73; 95 % CI: 0.66-0.81, p < 0.001). For PFS, a significant benefit was seen only in first-line treatment (HR: 0.62; 95 % CI: 0.58-0.67, p < 0.001) but not in second-line (HR: 0.89; 95 % CI: 0.76-1.04, p = 0.128), with a significant difference between treatment lines (p < 0.001). Most subgroups in our study demonstrated significant survival benefits, except for current smokers (HR: 0.58; 95 % CI: 0.31-1.09; p = 0.089). Finally, all CPS subgroups showed survival benefits in the first-line setting except those with CPS < 1 (PD-L1 negative). A similar pattern was observed in the second-line setting.</p><p><strong>Conclusions: </strong>PD-1/PD-L1 inhibitors significantly improve OS over chemotherapy in both first- and second-line advanced ESCC. PFS improved only in the first line. More effective therapies for the second line are still needed. Current smokers showed no survival benefit, unlike former or never smokers. OS benefit was absent in PD-L1-negative patients (CPS <1) and greatest in those with CPS ≥ 10.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104876"},"PeriodicalIF":5.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathology, immunosuppression and NK cell immunotherapy of non-small cell lung cancer.","authors":"Xinyu Wu, Sandro Matosevic","doi":"10.1016/j.critrevonc.2025.104870","DOIUrl":"10.1016/j.critrevonc.2025.104870","url":null,"abstract":"<p><p>Lung cancer is one of the leading causes of cancer incidence and mortality. Non-small lung cancer (NSCLC) makes up almost 80 % of lung cancer cases. Treatments for NSCLC have traditionally been restricted to surgeries, radiotherapy, and chemotherapy. However, despite these therapies being able to induce remission in a proportion of patients, many lung cancer patients experience tumor recurrence. To combat high relapse rates, the adoptive transfer of natural killer (NK) cells as NSCLC immunotherapy is attractive as these cells do not require antigen presentation, do not induce GvHD, and can be active in allogeneic settings. However, NSCLC response rates remain low because of the development of resistance mechanisms to NK cell attack. Much of the resistance stems from metabolic reprogramming occurring in the lung cancer tumor microenvironment, owing to aggressive metabolic activity of cancer cells resulting in the production of immunosuppressive metabolites and metabolic byproducts, including oncometabolites. Immune evasion via MHC loss and malignant transformation toward an immunosuppressive niche alters NK cell chemotaxis, reduces their recruitment and impairs their activation. Here, we discuss NSCLC pathophysiology, the immune crosstalk in the NSCLC TME, as well as how the TME, particularly oncometabolite-mediated immunosuppression, metabolic reprogramming and immune dysfunction regulates therapeutic responses and NK cell functional alterations in NSCLC to ultimately drives response resistance.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104870"},"PeriodicalIF":5.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of systemic treatment with or without immune checkpoint inhibitors for advanced or recurrent endometrial cancer: A systematic review and meta-analysis of randomized controlled trials.","authors":"Mohammed Amine Saâd, Imad Taleb, Sofia El Omri, Hamadoun Traoré, Imane Chahbounia, Abdelkarim Antari, Imane Sella, Loubna Omri, Choukri Elm'hadi, Saïda Lamine, Mohammed Anouar Mokhlis, Lamia Aalaoui, Mohamed Reda Khmamouche, Khaoula Alaoui Slimani, Yassir Sbitti, Tarik Mahfoud, Hassan Errihani, Mohamed Ichou, Rachid Tanz","doi":"10.1016/j.critrevonc.2025.104873","DOIUrl":"10.1016/j.critrevonc.2025.104873","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have revolutionized gynecologic oncology, but their value in endometrial cancer remains unclear. We conducted this systematic review and meta-analysis to evaluate the efficacy and safety of ICIs in combination with systemic treatment in this setting.</p><p><strong>Methods: </strong>We searched phase II and III randomized controlled trials comparing systemic therapy with or without ICIs for advanced or recurrent endometrial cancer. We conducted this meta-analysis in two stages, first evaluating any therapy with or without ICIs, then a comparison of chemotherapy alone or with ICIs only. The primary objective of our analysis was to evaluate progression-free survival (PFS) and overall survival (OS). Hazard ratios (HRs) were pooled using random-effects models. Individual patient data were reconstructed from Kaplan-Meier curves for further survival analysis. This meta-analysis is registered in PROSPERO (CRD42025649698).</p><p><strong>Results: </strong>Six trials with a total of 3826 patients were included in this meta-analysis. In the intention-to-treat population, ICIs improved PFS with HR 0.71 [0.63; 0.81] 95 % confidence interval (95 % CI), p < 0.00001 and OS HR 0.79 [0.68; 0.93], p = 0.004. For dMMR patients, the benefit was pronounced for PFS, HR 0.40 [0.32; 0.49], p < 0.00001 and OS, HR 0.44 [0.33; 0.57], p < 0.00001. For pMMR patients, PFS was improved with HR 0.76, p = 0.002, but no survival benefit with HR at 0.90, p = 0.18.</p><p><strong>Conclusion: </strong>The addition of ICIs to chemotherapy for advanced or recurrent endometrial cancer significantly improves outcomes, especially for patients with a dMMR profile. For pMMR patients, the gain in PFS was evident, but OS remained immature.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104873"},"PeriodicalIF":5.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fatty acid in the tumor microenvironment: Perspectives for immunotherapy.","authors":"Ting Li, Yi-Ran Bie, Shan-Mei Chen, Yao Shang, Pei-Shan Hu","doi":"10.1016/j.critrevonc.2025.104878","DOIUrl":"10.1016/j.critrevonc.2025.104878","url":null,"abstract":"<p><p>Fatty acids (FA) are essential macromolecules in living organisms and play critical roles in processes such as cancer development, inflammation, and autoimmunity. Immune responses and metabolic changes are involved in tumor occurrence, development, invasion, and metastasis, and therapies targeting immunity and metabolism have gradually begun to be developed in clinical practice. Recent studies have revealed alterations in fatty acid metabolism in tumor microenvironment, suggesting that the modulation of fatty acid metabolism can affect the efficacy of immunotherapy. In this review, we summarize the effects of fatty acids on cancer immunotherapy in aspects including tumor cell metabolism, protein lipid modification, and clinical applications. A deeper understanding of the mechanisms by which FA and their metabolites participate in immune response can enhance our knowledge of their function in tumor development and their impact on the immune system, thereby providing new strategies for improving cancer immunotherapy.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104878"},"PeriodicalIF":5.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in nanoparticles with a PD-L1-based therapy combination of chemotherapy for lung cancer.","authors":"Abdulkareem Shareef, Hayder Naji Sameer, Ahmed Yaseen, Zainab H Athab, Mohaned Adil, Omer Qutaiba B Allela","doi":"10.1016/j.critrevonc.2025.104872","DOIUrl":"10.1016/j.critrevonc.2025.104872","url":null,"abstract":"<p><p>Globally, lung cancer (LC) continues to be the primary cause of cancer-related fatalities. The clinical use of immune checkpoint inhibitors (ICIs) in the treatment of small cell lung cancer (SCLC) follows significantly behind that of non-small cell lung cancer (NSCLC). In advanced NSCLC, combining chemotherapy (CHT) with PD-L1 inhibitors has increased overall survival (OS) and progression-free survival, especially in patients with high PD-L1 expression. Additionally, a new standard of therapy for extensive-stage SCLC has been authorized for atezolizumab in combination with carboplatin and etoposide. However, the combination of PD-L1 inhibitors plus CHT raises the risk of toxicities associated with CHT as well as immune-related side effects such as hepatitis, colitis, and pneumonitis. To minimize side effects, using nanoparticles (NPs) for medication delivery in immunochemotherapy for LC is crucial. In preclinical applications, NPs with transport and/or immunomodulation capabilities have been effectively integrated with ICT. Delivery NPs safeguard and regulate the intended release of their cargo. Generally speaking, we have examined the various ICHT-based LC treatment options in this research. The types of NPs available to mitigate the limitations of this treatment for LC have been studied. Lastly, we covered the clinical constraints and strategies to reduce them. This review article combines evidence from a wide range of sources, including PubMed/NCBI, Google Scholar, and ClinicalTrials.gov, all published within the last few years.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104872"},"PeriodicalIF":5.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}